Additional Markers Sample Clauses

Additional Markers. In the event that Sequenom or any Sequenom Affiliate(s), as applicable, proposes to add new diagnostic marker(s) that improve the sensitivity and/or specificity of a Licensed Product and, in connection therewith, it would be necessary for Sequenom or such Sequenom Affiliate(s) to obtain a license to any intellectual property rights of a Third Party not otherwise constituting a Third Party License, then Sequenom may notify Optherion thereof in writing, in which case Optherion shall use commercially reasonable efforts to negotiate an amendment to the In-License Agreements (and corresponding amendments to this Agreement that provide for sharing by Sequenom and Optherion of any reductions in payments under the In-License Agreements) in order to make the addition of such marker(s) commercially and otherwise desirable to Optherion and Sequenom.
Sample 1
AutoNDA by SimpleDocs
Additional Markers. Each party will use its best efforts to identify additional clinically relevant markers based on the Licensed Technology with application in the Field (e.g. [***]) (each, a “New Marker”) which will strengthen the results of the tests generated using the Licensed Technology. Subject to any confidentiality obligations with Third Parties, each party shall keep the other fully informed as to its discovery and/or development of any New Marker. All information disclosed in connection therewith shall be deemed Confidential Information hereunder and will be subject to applicable confidentiality obligations between the parties. Under the guidance of the Steering Committee, the parties will execute a statement of work which will set forth the respective rights of the parties with respect to the New Marker and the specific terms relating to the development and/or commercialization thereof; provided, however, that (i) if either party (a) discovers and/or (b) licenses from a Third Party a New Marker, such party shall retain ownership of (or the license rights to) such New Marker upon any termination or expiration of this Agreement; and (ii) in no event shall Clarient be required to pay any royalty to Prediction Sciences with respect to the increase in the price of the Licensed Solution to the extent such increase is due to the inclusion of any New Marker (a) discovered and/or (b) licensed from a Third Party by Clarient.
Sample 1

Related to Additional Markers

  • Nasdaq National Market Listing The shares of Parent Common Stock issuable to the Company stockholders pursuant to this Agreement shall have been authorized for listing on the Nasdaq National Market upon official notice of issuance.

  • Nasdaq National Market The Common Stock is listed on the Nasdaq National Market System, and there are no proceedings to revoke or suspend such listing.

  • Stock Exchange Delisting Prior to the Closing Date, the Company shall cooperate with Parent and use reasonable efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Laws and rules and policies of the NASDAQ Global Select Market to enable the delisting by the Surviving Corporation of the Shares from the NASDAQ Global Select Market and the deregistration of the Shares under the Exchange Act as promptly as practicable after the Effective Time.

  • Stock Exchange De-listing Prior to the Closing Date, the Company shall cooperate with Parent and use reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Laws and rules and policies of the NYSE to enable the delisting by the Surviving Corporation of the Shares from the NYSE and the deregistration of the Shares under the Exchange Act as promptly as practicable after the Effective Time.

  • Stock Exchange Delisting; Deregistration Prior to the Closing Date, the Company shall cooperate with Parent and use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable laws and rules and policies of NASDAQ to enable the delisting by the Surviving Corporation of the Shares from NASDAQ and the deregistration of the Shares under the Exchange Act as promptly as practicable after the Effective Time.

  • AMEX Listing The Public Securities shall have been approved for listing on AMEX.

  • Nasdaq Until the consummation of a Business Combination, the Company will use its best efforts to maintain the listing of the Public Securities on Nasdaq or a national securities exchange acceptable to the Representative.

  • Obtaining Stock Exchange Listings The Company will from time to time take all commercially reasonable actions which may be necessary so that the Warrant Shares, immediately upon their issuance upon the exercise of Warrants, will be listed on the principal securities exchanges and markets within the United States of America, if any, on which other shares of Common Stock are then listed.

  • Listing on the Nasdaq Capital Market The Company will use commercially reasonable efforts to maintain the listing of the Public Securities on the Nasdaq Capital Market or another national securities exchange until the earlier of five (5) years from the Effective Date or until the Public Securities are no longer registered under the Exchange Act.

  • Stock Exchange Listings Parent shall use all reasonable efforts to list on the NYSE, upon official notice of issuance, the Paired Shares to be issued in connection with the Merger.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!